L

Labiana Health SA
MAD:LAB

Watchlist Manager
Labiana Health SA
MAD:LAB
Watchlist
Price: 3.92 EUR Market Closed
Market Cap: 28.3m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LAB stock under the Base Case scenario is 8.51 EUR. Compared to the current market price of 3.92 EUR, Labiana Health SA is Undervalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAB Relative Value
Base Case
8.51 EUR
Undervaluation 54%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

0.4
P/S
P/S
Price to Sales
0.4
vs History
0
vs Industry
87
Median 3Y
0.2
Median 5Y
0.2
Industry
2.7
Forward
0.4
More Details
106.9
P/E
P/E
Price to Earnings
106.9
vs History
0
vs Industry
Median 3Y
-18.5
Median 5Y
-18.7
Industry
22.2
Forward
8.8
More Details
3.8
P/OCF
P/OCF
Price to OCF
3.8
vs History
0
vs Industry
47
Median 3Y
-13.4
Median 5Y
-13.5
Industry
17.2
More Details
0.7
P/FCFE
P/FCFE
Price to FCFE
0.7
vs History
0
vs Industry
Median 3Y
-6.3
Median 5Y
-6.3
Industry
23.9
More Details
7.7
P/B
P/B
Price to Book Value
7.7
vs History
0
vs Industry
16
Median 3Y
2.9
Median 5Y
2.9
Industry
2.3
More Details
0.3
EV/S
EV/S
Enterprise Value to Sales
0.3
vs History
10
vs Industry
89
Median 3Y
0.2
Median 5Y
0.2
Industry
2.9
Forward
0.3
More Details
0.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
0.5
vs History
12
vs Industry
87
Median 3Y
0.4
Median 5Y
0.4
Industry
5.6
More Details
2.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
2.3
vs History
20
vs Industry
51
Median 3Y
1.5
Median 5Y
1.5
Industry
13.3
Forward
2.1
More Details
4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4
vs History
10
vs Industry
46
Median 3Y
-11.3
Median 5Y
-12.5
Industry
16.7
Forward
2.9
More Details
3.1
EV/OCF
EV/OCF
Enterprise Value to OCF
3.1
vs History
0
vs Industry
42
Median 3Y
-12.6
Median 5Y
-12.7
Industry
15.8
More Details
5.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
5.3
vs History
0
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
17.8
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
35
vs Industry
74
Median 3Y
0.5
Median 5Y
0.5
Industry
2
More Details

Multiples Across Competitors

LAB Competitors Multiples
Labiana Health SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Labiana Health SA
MAD:LAB
27.1m EUR 0.4 106.9 2.3 4
US
Eli Lilly and Co
NYSE:LLY
673.8B USD 12.7 48.8 29 31.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
431.3B USD 4.8 19 14.5 19
CH
Roche Holding AG
SIX:ROG
208B CHF 3.4 25.1 9.4 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 14.5 10.6 11.8
UK
AstraZeneca PLC
LSE:AZN
185.6B GBP 4.4 30.3 114.5 169.9
CH
Novartis AG
SIX:NOVN
197.4B CHF 4.5 18 10.8 14.4
US
Merck & Co Inc
NYSE:MRK
219.8B USD 3.5 13.4 8.6 10.2
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
147.1B USD 2.3 13.7 7.7 10.5
P/E Multiple
Earnings Growth PEG
ES
L
Labiana Health SA
MAD:LAB
Average P/E: 32.2
106.9
211%
0.5
US
Eli Lilly and Co
NYSE:LLY
48.8
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19
27%
0.7
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
18%
0.8
UK
AstraZeneca PLC
LSE:AZN
30.3
36%
0.8
CH
Novartis AG
SIX:NOVN
18
16%
1.1
US
Merck & Co Inc
NYSE:MRK
13.4
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.7
30%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
L
Labiana Health SA
MAD:LAB
Average EV/EBITDA: 395
2.3
21%
0.1
US
Eli Lilly and Co
NYSE:LLY
29
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.5
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
13%
0.8
UK
AstraZeneca PLC
LSE:AZN
114.5
10%
11.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.6
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
L
Labiana Health SA
MAD:LAB
Average EV/EBIT: 1 701.5
4
36%
0.1
US
Eli Lilly and Co
NYSE:LLY
31.4
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19
14%
1.4
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
14%
0.8
UK
AstraZeneca PLC
LSE:AZN
169.9
23%
7.4
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
US
Merck & Co Inc
NYSE:MRK
10.2
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
9%
1.2

See Also

Summary
LAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
LAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LAB stock valuation using valuation multiples.
Wall Street Estimates
LAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 277,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.